Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
LeMaitre Vascular (NASDAQ:LMAT - Get Rating) was downgraded by investment analysts at StockNews.com from a "buy" rating to a "hold" rating in a report issued on Tuesday.LeMaitre Vascular Trading Up 0.1 %
LMAT stock traded up $0.06 during mid-day trading on Tuesday, reaching $49.17. The company's stock had a trading volume of 87,036 shares, compared to its average volume of 108,714. The company has a market cap of $1.08 billion, a price-to-earnings ratio of 48.68, a price-to-earnings-growth ratio of 4.22 and a beta of 1.19. The business's 50 day moving average price is $50.73 and its 200 day moving average price is $46.98. LeMaitre Vascular has a 12 month low of $38.32 and a 12 month high of $56.47. Insider Buying and Selling at LeMaitre Vascular
In other LeMaitre Vascular news, CEO George W. Lemaitre sold 6,890 shares of the firm's stock in a transaction that occurred on Wednesday, August 17th. The stock was sold at an average price of $52.67, for a total value of $362,896.30. Following the completion of the sale, the chief executive officer now owns 2,480,908 shares of the company's stock, valued at $130,669,424.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO George W. Lemaitre sold 17,702 shares of LeMaitre Vascular stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $55.89, for a total transaction of $989,364.78. Following the transaction, the chief executive officer now owns 2,507,476 shares of the company's stock, valued at $140,142,833.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO George W. Lemaitre sold 6,890 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $52.67, for a total value of $362,896.30. Following the transaction, the chief executive officer now directly owns 2,480,908 shares in the company, valued at approximately $130,669,424.36. The disclosure for this sale can be found here. Over the last quarter, insiders sold 64,633 shares of company stock valued at $3,534,996. Company insiders own 12.50% of the company's stock. Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. Everence Capital Management Inc. purchased a new position in LeMaitre Vascular in the first quarter worth $257,000. Personal CFO Solutions LLC boosted its position in LeMaitre Vascular by 4.4% in the first quarter. Personal CFO Solutions LLC now owns 6,485 shares of the medical instruments supplier's stock worth $301,000 after purchasing an additional 275 shares during the last quarter. Rice Hall James & Associates LLC boosted its position in LeMaitre Vascular by 2.7% in the first quarter. Rice Hall James & Associates LLC now owns 261,873 shares of the medical instruments supplier's stock worth $12,169,000 after purchasing an additional 6,781 shares during the last quarter. Grandeur Peak Global Advisors LLC boosted its position in LeMaitre Vascular by 0.9% in the fourth quarter. Grandeur Peak Global Advisors LLC now owns 314,076 shares of the medical instruments supplier's stock worth $15,776,000 after purchasing an additional 2,931 shares during the last quarter. Finally, Legacy Wealth Asset Management LLC boosted its position in LeMaitre Vascular by 4.6% in the second quarter. Legacy Wealth Asset Management LLC now owns 18,388 shares of the medical instruments supplier's stock worth $838,000 after purchasing an additional 811 shares during the last quarter. Hedge funds and other institutional investors own 88.45% of the company's stock. LeMaitre Vascular Company Profile (Get Rating)
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system.Further ReadingGet a free copy of the StockNews.com research report on LeMaitre Vascular (LMAT)Build A Better Tech Portfolio With Jabil Inc.Is There Value In These Growth Stocks?Autodesk Is A Mature Company Still Acting Like A Growth StockMarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMCIs the Market Overreacting with Shopify Stock?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider LeMaitre Vascular, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LeMaitre Vascular wasn't on the list.
While LeMaitre Vascular currently has a "N/A" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:
Axel Merk, President and CIO of Merk Investments has three very different stocks he frames within the current market and economic conditions.
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.